Literature DB >> 11144395

Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.

D R Guay1.   

Abstract

BACKGROUND: Oral second and third generation cephalosporins are undergoing continuing research and development in the arena of pediatric infectious disease in an attempt to fill voids created by existing agents in the quest for the "ideal" antimicrobial. This paper reviews the in vitro antimicrobial activity (pharmacodynamics) and pharmacokinetics of cefdinir, an extended spectrum oral cephalosporin, with an emphasis on those aspects relevant to the pediatric patient population.
METHODS: A MEDLINE literature search was conducted for the years 1985 through 2000, identifying all English language papers examining the in vitro antimicrobial activity and human pharmacokinetics of cefdinir. Bibliographies of these papers were reviewed, as were relevant data on file with the manufacturer. DATA SYNTHESIS: Cefdinir exhibits broad range in vitro activity against Gram-positive and Gram-negative aerobes. It exhibits superior activity against Gram-positive aerobes, compared with drugs like cefixime, ceftibuten, cefuroxime and cefpodoxime. In addition it is stable to hydrolysis by many of the common betalactamases. The pharmacokinetic parameters of cefdinir in children are similar to those obtained in adults using similar milligram per m2 doses (300, 600 mg in adults = 7, 14 mg/kg in children, respectively).
CONCLUSIONS: The pharmacodynamic and pharmacokinetic characteristics of cefdinir as described in this paper, as well as the results of the clinical trials program, support the use of this agent in the treatment of a wide variety of pediatric infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144395     DOI: 10.1097/00006454-200012001-00002

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.

Authors:  Edouard Bingen; Philippe Bidet; André Birgy; Elsa Sobral; Patricia Mariani; Robert Cohen
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 2.  Applying Pharmacodynamics and Antimicrobial Stewardship to Pediatric Preseptal and Orbital Cellulitis.

Authors:  Grant T Stimes; Jennifer E Girotto
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

Review 3.  Formulations of antibiotics for children in primary care: effects on compliance and efficacy.

Authors:  Andres Ramgoolam; Russell Steele
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney.

Authors:  Christopher S Lepsy; Robert J Guttendorf; Alan R Kugler; David E Smith
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 5.  Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Authors:  Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Design and development of cefdinir niosomes for oral delivery.

Authors:  Saurabh Bansal; Geeta Aggarwal; Pankaj Chandel; S L Harikumar
Journal:  J Pharm Bioallied Sci       Date:  2013-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.